Tyra Biosciences, Inc. (TYRA)
US — Healthcare Sector
Automate Your Wheel Strategy on TYRA
With Tiblio's Option Bot, you can configure your own wheel strategy including TYRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TYRA
- Rev/Share 0.0
- Book/Share 5.4525
- PB 1.8945
- Debt/Equity 0.0189
- CurrentRatio 22.783
- ROIC -0.345
- MktCap 548419256.0
- FreeCF/Share -1.2428
- PFCF -7.4366
- PE -6.356
- Debt/Assets 0.0178
- DivYield 0
- ROE -0.2745
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | TYRA | Piper Sandler | -- | Overweight | -- | $33 | May 21, 2025 |
| Initiation | TYRA | UBS | -- | Buy | -- | $28 | Jan. 7, 2025 |
| Upgrade | TYRA | BofA Securities | Neutral | Buy | $22 | $31 | Oct. 18, 2024 |
News
About Tyra Biosciences, Inc. (TYRA)
- IPO Date 2021-09-15
- Website https://www.tyra.bio
- Industry Biotechnology
- CEO Dr. Todd Harris Ph.D.
- Employees 60
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.